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1LETTER TO THE EDITOR
econstitution of T Cell Subset Repertoire Diversity
ollowing Multiple Antigen-Mismatched Bone
arrow Transplantation
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tIn allogeneic blood and bone marrow transplan-
ation (BMT), patients lacking an available HLA-
atched sibling donor must resort to a related hap-
oidentical donor or an unrelated individual who is
LA-matched or multiple antigen-mismatched. In
hese situations, the likely development of graft-versus-
ost disease (GVHD) can be avoided by T cell depletion
f the donor inoculum. Unfortunately, T cell depletion
s usually accompanied by an increased risk of leukemic
elapse, engraftment failure, and severe prolonged
mmunodeﬁciency, thus eliminating any survival ad-
antage [1]. Approaches to overcome these obstacles
ave included partial T cell depletions using mono-
lonal antibodies (T10B9 [2], anti-CD6 [3], and Cam-
ath-1H [4]), antithymocyte globulin (ATG) [5],
igh-dose CD34 cell transplantation [6], and limited
cell add-backs or donor lymphocyte infusions [7,8].
hese approaches have shown some success in pro-
oting engraftment, decreasing GVHD, and promot-
ng graft-versus-leukemia effects. However, little is
nown about the reconstitution of T cell repertoire
omplexity in patients receiving multiple antigen-mis-
atched CD34-selected transplants, with limited T
ell add-back at the time of transplantation, particu-
arly in the unrelated donor setting.
In this regard, we studied 2 male patients, M1 (31
ears old; myelodysplastic syndrome; international
rognostic scoring system high, 28% myeloblasts/
oor risk cytogenetics) and M2 (55 years old, chronic
yelogenous leukemia blast crisis, failed imatinib
herapy), who had high-risk malignancies, no matched
onors, and consented to receive multiple, antigen
olecularly mismatched, unrelated, marrow stem cell
rafts (disparities, M1 at B/DR/DQ and M2 at A/DQ)
ith limited T cell add-back at the time of transplan-
ation. Donors were female and male for M1 and M2,
espectively. Both patients received transplant condi-
ioning with busulfan/cyclophosphamide and rabbit-
erived ATG (3 mg/kg, days 4 and 3). Bone mar-
ow was harvested and T cell depletion was performed
y CD34 immunomagnetic selection using the
solex 300 system (Baxter, Deerﬁeld, IL). M1 and M2
eceived 1  106 and 7.2  105 CD34 cells/kg, h
092espectively. Numbers of CD3 cells in the stem cell
noculum were undetectable for M1 and 1  103 for
2. Both patients were given 1  105 CD3 cells
rom the CD34 fraction as add-back at the time of
ransplantation. In addition, M2 was given a stem cell
oost of 6.1  106 CD34 cells/kg 90 days after the
riginal transplantation. GVHD prophylaxis in-
luded standard tacrolimus and methotrexate with
rednisone (0.5 mg/kg starting on day 7 and ta-
ering off by day 90) and intravenous immuno-
lobulin.
After transplantation, patients M1 and M2 achieved
eutrophil counts of 1000 cells/L (days 15 and 26,
espectively). Neither patient developed detectable
cute or chronic GVHD and both were long-term,
linical, disease-free survivors with complete blood
ounts and differentials within the normal range. Nei-
her survivor developed any serious late infection and
oth had undetectable or nonsustained low levels of
pstein-Barr virus DNA. Immunoglobulin (G, A, and
) levels measured at 1 and 2 years after transplanta-
ion were within the normal range for both patients,
xcept for a low immunoglobulin A level (29 mg/dL)
or M2. At 40 months after transplantation, M1 ex-
ibited 100% donor hematopoietic chimerism, as de-
ermined by ﬂuorescence in situ hybridization analysis
or the Y chromosome, and had normal T and B cell
ounts (CD3, CD8, and CD19) with a borderline low
D4 count (507 cells/mm3). At 25 months, M2 had
ormal CD3 and CD8 counts, increasing CD4 counts
260 cells/mm3), and improving chimerism (CD33
00% donor; CD3 33% donor). Flow cytometric
nalysis using monoclonal antibodies to the CD45RA
nd CD45RO protein indicated that 70% and 30% of
he CD8 T cells were of naive (CD45RA) and mem-
ry (CD45RO) phenotype, respectively, in M1 and
2. In contrast, in the CD4 subset, the numbers of
aive and memory T cells were equal (50%) in both
atients.
The apparent absence of acute GVHD could
ikely be connected to the addition of rabbit ATG in
he transplant conditioning regimen. This association
as been previously reported in a study of haploiden-
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Letter to the Editor 1093ical transplantation outcomes [9] Regarding the lack
f chronic GVHD, our observations are consistent
ith those of other reports suggesting a lower associ-
tion of bone marrow-derived stem cells with chronic
VHD as compared with its incidence in patients
eceiving peripheral blood stem cell transplants, re-
ardless of differences in HLA disparity [9-12].
T cell receptor V CDR3-size spectratype analy-
is is a highly sensitive tool for examining T cell
eceptor diversity and has been used as a means of
haracterizing the complexity of T cell repertoire re-
onstitution after BMT [13]. In general, spectratype
nalysis generates 6-10 different size classes of CDR3-
igure 1. Four representative spectratype histograms from V famil
cell subsets from a control individual and from patients M1 and M2.ength polymerase chain reaction products for each
 family, and the complexity of the T cell repertoire
orrelates with the larger number of different-sized
roducts (Figure 1). Peripheral blood lymphocytes
ere enriched from blood samples from M1 and M2
t 40 and 25 months after transplantation, respec-
ively. The CD4 and CD8 T cell subsets were
eparated by immunomagnetic cell sorting and total
NA was used to perform semi-nested reverse tran-
cription polymerase chain reaction with a panel of
uman V sense and 2 C antisense oligoprimers [13]
nd fragment analysis was performed with Genemap-
er software (Applied Biosystems, Foster City, CA).
, 11, and 23 indicating repertoire complexity for the CD8 and CD4ies 2, 8
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Letter to the Editor1094eripheral blood lymphocytes were similarly collected
nd analyzed from 6 healthy donors as representative
f a fully complex repertoire. The complexity index
ithin a V family was determined as a percentage of
he number of peaks found in the spectratype histo-
ram of the patient in relation to the average number
f peaks in the corresponding histograms of the 6
ealthy donors. Any V family with a complexity
ndex 60% was considered to be complex. CDR3-size
pectratype analysis was used to examine the reconstitut-
ng complexity of V families in the CD4 and CD8 T
ell subsets. For the 21-23 resolvable V families, the
esults (Table 1) demonstrated overall complexities of
1% (M1) and 82% (M2) in the CD4 compartment and
6% (M1) and 73% (M2) in the CD8 compartment.
hese levels of repertoire complexity in the 2 patients
uggests a sufﬁcient level of T cell reconstitution and
mmunocompetency. The level of complexity we ob-
erved compares favorably to what has been previously
eported regarding T cell repertoire reconstitution for T
ell-depleted matched sibling transplantation, where
omplexity does not begin to evolve until 12 months
fter transplantation and for 33% of patients examined
oes not normalize until 2 or 3 years later [14].
It should be noted that there is a high rate of
ransplant-related mortality due to infectious disease
n multiple antigen-mismatched BMT [9,10]. This
able 1. Summary of T Cell Repertoire Reconstitution Complexity
V Family
CD8 CD4
M1 M2 M1 M2
1  ND  ND
2    
3    
4    
5    
6    
7    
8    
9    
10 ND   
11    
12    
13    
14    
15    
16    
17    
18    
19    
20 ND ND ND ND
21    
22    
23    
24 ND   
Overall complexity 86% 70% 91% 82%
Indicates a complexity index 60% for the V family; , com-
plexity index 60% for the V family; ND, spectratype could1not be determined (resolved) for that V family.igh transplant-related mortality is closely associated
ith the lack of immune reconstitution and is likely
elated to the more aggressive donor T cell-depletion
pproaches used to prevent the development of acute
VHD [15]. Controlled T cell add-backs at the time
f transplantation, as described in this report, might
acilitate more extensive T cell repertoire reconstitu-
ion and improve transplantation outcomes for multi-
le antigen-mismatched transplant patients. We re-
ort that recipients of multiple antigen-mismatched
rafts can establish a diverse and complex CD4 and
D8 T cell repertoire. The implications for improved
linical outcomes warrant further study in a larger
ohort of patients.
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